# Eric Urhane

> Eric Urhane is a seed investor backing Software, Health Care and Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Total investments: 5
- Last investment: Mar 2019
- Lead investor: 0%
- Last updated: Aug 2026

Eric Urhane is a seed investor focused on Software and Health Care. Eric Urhane

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.1M–$1.9M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 2 | 40% |
| Health Care | 2 | 40% |
| Biotechnology | 2 | 40% |
| Cloud Computing | 2 | 40% |
| Health Diagnostics | 2 | 40% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 60% |
| Angel | 2 | 40% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 60% |
| Mexico | 1 | 20% |
| Singapore | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Unima | Unima is decentralizing rapid testing across industries by taking diagnostics out of the lab to the place these are needed the most to secure a timely diagnostic for everyone, anywhere.Unima is solving is the centralization of lab testing, which limits the access to a timely diagnostic for billions. Current technology for diagnostics is veryprecise and can detect almost any disease known, but the problem is these require labs with expensive equipment and specialized technicians making lab testing impossible to scale up to provide universal and timely access to diagnostics.To solve this problem Unima developed Find, a rapid testing technology platform for real time diagnostics which allows anyone to diagnose a disease directly where it is needed, without using lab equipment, with results in 15 minutes or less and at a very low cost. With Find anyone can have access to a timely diagnostic even in the most remote areas of the world.The Find platform uses shark antibodies modified with genetic engineering to detect disease biomarkers in blood, saliva, urine or water samples. These shark antibodies are used in microfluidic cards and generate a visual reactions when in contact with specific biomarkers of the disease to be tested. Then to evaluate the result of the test, a picture of the testing card is taken with the proprietary Xplora smartphone app which runs image analysis process and neural network algorithms to generate an inmediate result. Then this result,along with contextual information like geolocation, date and time, is sent to a cloud server where it can be used for real time disease tracking. | $1.9M | Seed | Mar 24, 2019 |  |
| X-ZELL | X-ZELL’s vision is to save lives by identifying clinically significant cancers early, when there is still time to act and take charge of our health.X-ZELL first made headlines in 2017 when it found a way to routinely locate tumour-associated Circulating Endothelial Cells (tCEC) in a small, 10mL blood sample. Known to be powerful biomarkers forthe early detection of aggressive cancers, tCEC were long considered ‘undetectable’ in clinical routine. X-ZELL overcame the impasse by developing a platform technology that is capable of detecting a single tCEC among five billion healthy blood cells and analysing it using Artificial Intelligence – making for an affordable, non-invasive solution with maximum scalability. Less than a year after that breakthrough, X-ZELL was able to present the world’s first tCEC-based blood test for the early detection of clinically significant prostate cancer – X-ZELL™ Prostate. But one cancer is not enough. X-ZELL’s ambition is to make accurate, affordable tCEC screening available to everyone, everywhere – which is why additional tests for common cancers such as breast, ovarian, colon and lung have already gone into pre-development, with more to come. They all feed into the creation of an AI-driven general screening test that will be able to scrutinise our blood for atypical cells and analyse them on-screen – allowing physicians to manage our health proactively instead of just responding to a disease. | $1.3M | Seed | Mar 22, 2016 |  |
| Chirply | Chirply is a platform for crowd-sourcing & crowd-curating design. Chirply's mission is to build engagement, stickiness, and virality through crowd-sourcing design. Initially the company focused on the launch of a marketplace for crowd-sourced design for paper goods - an industry that hasn't been disrupted since the advent of theprinting press. Chirply then launched a B2B platform for crowd-sourced design for brands to help engage users and use design to make daily products inspiring. | $1.1M | Seed | Apr 07, 2011 |  |
| dotCloud | DotCloud is a 2nd-generation platform-as-a-service, and is the commercial entity behind Docker.io. Docker is an open source engine that makes it possible to pack, ship, and run any application as a lightweight container. |  | Angel | Feb 28, 2011 |  |
| Docker | Docker develops an open platform for building, shipping, and running distributed applications. Its platform allows developers and system administrators to create and run applications as a collection of containers that work across laptops, data center virtual machines, and public cloud instances. Docker also offers an application run-time andpackaging tool and a cloud service for sharing applications and automating workflows.Starting in 2008, dotCloud became Docker in October 2013, with its headquarters in San Francisco, California. | $800K | Angel | Feb 28, 2011 |  |

5 of 5 investments shown.

## Co-investors
- [Y Combinator](https://shizune.co/investors/profile/y-combinator) — VC Fund, 2 deals together
- [Avalancha Ventures](https://shizune.co/investors/profile/avalancha-ventures) — VC Fund, 1 deal together
- [Dadneo](https://shizune.co/investors/profile/dadneos) — VC Fund, 1 deal together
- [Venturance Alternative Assets](https://shizune.co/investors/profile/fondo-alerce-venture-capital) — VC Fund, 1 deal together
- [Fondo Vulcano](https://shizune.co/investors/profile/fondo-vulcano) — VC Fund, 1 deal together
- [Genesis Capital Ventures](https://shizune.co/investors/profile/genesis-capital-venture) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Seeds Capital](https://shizune.co/investors/profile/seeds-capital) — VC Fund
- [Wavemaker Ventures](https://shizune.co/investors/profile/wavemaker-partners) — VC Fund

## Featured in investor lists
- [Medical Angel Investors in Singapore](https://shizune.co/investors/medical-angel-investors-singapore)
- [Medical Device Angel Investors in Asia](https://shizune.co/investors/medical-device-angel-investors-asia)
- [Medical Device Angel Investors in Singapore](https://shizune.co/investors/medical-device-angel-investors-singapore)
- [Biotechnology Angel Investors in Asia](https://shizune.co/investors/biotechnology-angel-investors-asia)
- [Biotechnology Angel Investors in LATAM](https://shizune.co/investors/biotechnology-angel-investors-latam)
- [Biotechnology Angel Investors in Mexico](https://shizune.co/investors/biotechnology-angel-investors-mexico)

## FAQ

### What does Eric Urhane invest in?

Eric Urhane invests primarily in Software, Health Care and Biotechnology startups, most often at Seed and Angel stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Eric Urhane's check size?

Eric Urhane typically joins rounds of $1.1M–$1.9M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Eric Urhane participates in.

### When did Eric Urhane last invest?

The most recent investment recorded for Eric Urhane closed in Mar 2019. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co